Fanelli G M, Bohn D L, Scriabine A, Beyer K H
J Pharmacol Exp Ther. 1977 Feb;200(2):402-12.
The saluretic and uricosuric responses elicited by a novel agent, MK-196, have been studied in a great ape, the chimpanzee. This agent is orally active at very low doses and has a prolonged duration of action. Probenecid does not appear to influence the saluretic and uricosuric properties of MK-196. Net tubular secretion of urate was reduced by MK-196. Urinary pH changes did not compromise the efficacy of this new agent. On a dose basis, MK-196 was more saluretic (and uricosuric) than ethacrynic acid or furosemide and possessed a longer duration of action. Because of the marked natriuresis caused by MK-196, some increase in potassium excretion occurred.
一种新型药物MK - 196引发的促尿钠排泄和促尿酸排泄反应已在一种大型猿类——黑猩猩身上进行了研究。这种药物在极低剂量下口服有效，且作用持续时间长。丙磺舒似乎不影响MK - 196的促尿钠排泄和促尿酸排泄特性。MK - 196可减少尿酸盐的肾小管净分泌。尿液pH值变化并未损害这种新药的疗效。按剂量计算，MK - 196比依他尼酸或呋塞米更具促尿钠排泄（和促尿酸排泄）作用，且作用持续时间更长。由于MK - 196引起显著的利钠作用，钾排泄有所增加。
